Skip to main content
. Author manuscript; available in PMC: 2023 May 5.
Published in final edited form as: Lancet Infect Dis. 2021 Jun 18;21(11):1579–1589. doi: 10.1016/S1473-3099(20)30997-X

Table 2. Kelch13 genotypes of P. falciparum positive samples from all survey rounds.

Screening (Month -2) Month 3 Month 5 Month 10 Month 15 Month 21 Month 27 Month 33
MDA Control MDA Control MDA Control MDA Control MDA Control MDA Control MDA Control MDA Control
N (Successful Amplification) 52 42 13 51 14 17 20 24 32 21 11 14 20 13 26 15
K13 Wild Type 24 (46) 15 (36) 6 (46) 20 (39) 3 (21) 5 (29) 7 (35) 11 (46) 6 (19) 6 (29) 4 (36) 4 (29) 6 (30) 2 (15) 14 (54) 5 (33)
K13 mutation 28 (54) 27 (64) 7 (54) 31 (61) 11 (79) 12 (71) 13 (65) 13 (54) 26 (81) 15 (71) 7 (64) 10 (71) 14 (70) 11 (85) 12 (46) 10 (67)
F446Ia 10 (19) 12 (29) 4 (31) 18 (35) 9 (64) 8 (47) 5 (25) 4 (17) 17 (53) 10 (48) 4 (36) 8 (57) 13 (65) 9 (69) 11 (42) 7 (47)
C580Ya 5 (10) 4 (10) 2 (15) 4 (8) 1 (7) 2 (12) 2 (10) 3 (13) 1 (3) 3 (14) 1 (9) 1 (5) 1 (8) 1 (4) 2 (13)
G449Ab 4 (8) 2 (4) 4 (20) 1 (4) 4 (13) 1 (5) 1 (7)
N537Ib 1 (2) 5 (12) 2 (4) 1 (6) 1 (7)
C469Fb 1 (2) 1 (2) 1 (2) 2 (10) 2 (8) 1 (3) 1 (9)
P553La 3 (6) 2 (5) 1 (3) 1 (9)
K438N 2 (4) 2 (5) 1 (2) 1 (6) 1 (4)
P574Lb 1 (8) 1 (2) 1 (11) 1 (4) 1 (7) 1 (8)
R561Ha 1 (2) 1 (4) 1 (5)
I205T 1 (2)
R575Kc 1 (2)
K586E/K 1 (2)
M476Ia 1 (2)
E321K 1 (3)
R528S/R 1 (3)

n (%) presented. K13 mutations are arranged in order of frequency of detection.

a

Validated resistance mutation 38

b

Candidate resistance mutation 38

c

Reported to be associated with delayed clearance but not statistically significant 38